| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 156, Issue 12 4697-4706, Copyright © 1996 by American Association of Immunologists
ARTICLES |
C Fayolle, P Sebo, D Ladant, A Ullmann and C Leclerc
Unit for Biology of Immunological Regulations, Pasteur Institute, Paris, France.
Exogenous Ags enter the endosomal pathway and are presented to CD4+ T cells in association with class II molecules whereas endogenously synthesized Ags, such as viral proteins, are presented to CD8+ T cells in association with MHC class I molecules. Therefore, most CTL activation strategies use live vectors although an alternative possibility could be to deliver the epitope into the cytosol by targeting it to an invasive nonreplicative vector. The adenylate cyclase toxin of Bordetella pertussis is able to invade a large number of eukaryotic cells and to deliver its catalytic domain to the cytosol of the cells. In the present study, we have tested the in vivo immunogenicity of recombinant adenylate cyclase toxins expressing CTL epitopes either from the nucleoprotein of lymphocytic choriomeningitis virus or from the V3 region of HIV-1 gp120. BALB/c mice immunized with these toxins developed high specific CTL responses that were shown to be mediated by class I-restricted CD8+ CTL. The induction of CTL responses by recombinant toxins did not require CD4+ T cells and the cytotoxic activity persisted 2 mo after immunization. The activation of CTL responses by the recombinant adenylate cyclase toxin required the full-length invasive activity of the toxin but did not depend upon its catalytic adenylate cyclase activity as demonstrated with a genetically inactivated recombinant toxin expressing the lymphocytic choriomeningitis virus epitope. This genetically detoxified invasive toxin represents, therefore, an attractive new vector for CTL activation.
This article has been cited by other articles:
|
|
 |
|
  S. Hervas-Stubbs, A. Olivier, F. Boisgerault, N. Thieblemont, and C. Leclerc TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help Blood, June 15, 2007; 109(12): 5318 - 5326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Lasarte, N. Casares, M. Gorraiz, S. Hervas-Stubbs, L. Arribillaga, C. Mansilla, M. Durantez, D. Llopiz, P. Sarobe, F. Borras-Cuesta, et al. The Extra Domain A from Fibronectin Targets Antigens to TLR4-Expressing Cells and Induces Cytotoxic T Cell Responses In Vivo J. Immunol., January 15, 2007; 178(2): 748 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Shaw and M. N. Starnbach Stimulation of CD8+ T Cells following Diphtheria Toxin-Mediated Antigen Delivery into Dendritic Cells Infect. Immun., February 1, 2006; 74(2): 1001 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mascarell, C. Fayolle, C. Bauche, D. Ladant, and C. Leclerc Induction of Neutralizing Antibodies and Th1-Polarized and CD4-Independent CD8+ T-Cell Responses following Delivery of Human Immunodeficiency Virus Type 1 Tat Protein by Recombinant Adenylate Cyclase of Bordetella pertussis J. Virol., August 1, 2005; 79(15): 9872 - 9884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Wilkinson, M. Simsova, E. Scholvinck, P. Sebo, C. Leclerc, H. M. Vordermeier, S. J. Dickson, J. R. Brown, R. N. Davidson, G. Pasvol, et al. Efficient Ex Vivo Stimulation of Mycobacterium tuberculosis-Specific T Cells by Genetically Detoxified Bordetella pertussis Adenylate Cyclase Antigen Toxoids Infect. Immun., May 1, 2005; 73(5): 2991 - 2998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Preville, D. Ladant, B. Timmerman, and C. Leclerc Eradication of Established Tumors by Vaccination With Recombinant Bordetella pertussis Adenylate Cyclase Carrying the Human Papillomavirus 16 E7 Oncoprotein Cancer Res., January 15, 2005; 65(2): 641 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schlecht, J. Loucka, H. Najar, P. Sebo, and C. Leclerc Antigen Targeting to CD11b Allows Efficient Presentation of CD4+ and CD8+ T Cell Epitopes and In Vivo Th1-Polarized T Cell Priming J. Immunol., November 15, 2004; 173(10): 6089 - 6097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Ross, E. C. Lavelle, K. H. G. Mills, and A. P. Boyd Adenylate Cyclase Toxin from Bordetella pertussis Synergizes with Lipopolysaccharide To Promote Innate Interleukin-10 Production and Enhances the Induction of Th2 and Regulatory T Cells Infect. Immun., March 1, 2004; 72(3): 1568 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Majlessi, M.-J. Rojas, P. Brodin, and C. Leclerc CD8+-T-Cell Responses of Mycobacterium-Infected Mice to a Newly Identified Major Histocompatibility Complex Class I-Restricted Epitope Shared by Proteins of the ESAT-6 Family Infect. Immun., December 1, 2003; 71(12): 7173 - 7177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dadaglio, S. Morel, C. Bauche, Z. Moukrim, F. A. Lemonnier, B. J. Van den Eynde, D. Ladant, and C. Leclerc Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes Int. Immunol., December 1, 2003; 15(12): 1423 - 1430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. El-Azami-El-Idrissi, C. Bauche, J. Loucka, R. Osicka, P. Sebo, D. Ladant, and C. Leclerc Interaction of Bordetella pertussis Adenylate Cyclase with CD11b/CD18: ROLE OF TOXIN ACYLATION AND IDENTIFICATION OF THE MAIN INTEGRIN INTERACTION DOMAIN J. Biol. Chem., October 3, 2003; 278(40): 38514 - 38521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Moron, P. Rueda, C. Sedlik, and C. Leclerc In Vivo, Dendritic Cells Can Cross-Present Virus-Like Particles Using an Endosome-to-Cytosol Pathway J. Immunol., September 1, 2003; 171(5): 2242 - 2250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dadaglio, C.-M. Sun, R. Lo-Man, C. A. Siegrist, and C. Leclerc Efficient In Vivo Priming of Specific Cytotoxic T Cell Responses by Neonatal Dendritic Cells J. Immunol., March 1, 2002; 168(5): 2219 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Loucka, G. Schlecht, J. Vodolanova, C. Leclerc, and P. Sebo Delivery of a MalE CD4+-T-Cell Epitope into the Major Histocompatibility Complex Class II Antigen Presentation Pathway by Bordetella pertussis Adenylate Cyclase Infect. Immun., February 1, 2002; 70(2): 1002 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fayolle, A. Osickova, R. Osicka, T. Henry, M.-J. Rojas, M.-F. Saron, P. Sebo, and C. Leclerc Delivery of Multiple Epitopes by Recombinant Detoxified Adenylate Cyclase of Bordetella pertussis Induces Protective Antiviral Immunity J. Virol., August 15, 2001; 75(16): 7330 - 7338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Etchart, P.-O. Desmoulins, K. Chemin, C. Maliszewski, B. Dubois, F. Wild, and D. Kaiserlian Dendritic Cells Recruitment and In Vivo Priming of CD8+ CTL Induced by a Single Topical or Transepithelial Immunization Via the Buccal Mucosa with Measles Virus Nucleoprotein J. Immunol., July 1, 2001; 167(1): 384 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Haicheur, E. Bismuth, S. Bosset, O. Adotevi, G. Warnier, V. Lacabanne, A. Regnault, C. Desaymard, S. Amigorena, P. Ricciardi-Castagnoli, et al. The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens J. Immunol., September 15, 2000; 165(6): 3301 - 3308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dadaglio, Z. Moukrim, R. Lo-Man, V. Sheshko, P. Sebo, and C. Leclerc Induction of a Polarized Th1 Response by Insertion of Multiple Copies of a Viral T-Cell Epitope into Adenylate Cyclase of Bordetella pertussis Infect. Immun., July 1, 2000; 68(7): 3867 - 3872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sedlik, G. Dadaglio, M. F. Saron, E. Deriaud, M. Rojas, S. I. Casal, and C. Leclerc In Vivo Induction of a High-Avidity, High-Frequency Cytotoxic T-Lymphocyte Response Is Associated with Antiviral Protective Immunity J. Virol., July 1, 2000; 74(13): 5769 - 5775. [Abstract] [Full Text]
|
|
|
|
|
|
T. Basar, P. Guermonprez, M. Rojas, and C. Leclerc Delivery of CD8+ T-Cell Epitopes into Major Histocompatibility Complex Class I Antigen Presentation Pathway by Bordetella pertussis Adenylate Cyclase: Delineation of Cell Invasive Structures and Permissive Insertion Sites Infect. Immun., January 1, 2000; 68(1): 247 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Doling, J. D. Ballard, H. Shen, K. M. Krishna, R. Ahmed, R. J. Collier, and M. N. Starnbach Cytotoxic T-Lymphocyte Epitopes Fused to Anthrax Toxin Induce Protective Antiviral Immunity Infect. Immun., July 1, 1999; 67(7): 3290 - 3296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fayolle, D. Ladant, G. Karimova, A. Ullmann, and C. Leclerc Therapy of Murine Tumors with Recombinant Bordetella pertussis Adenylate Cyclase Carrying a Cytotoxic T Cell Epitope J. Immunol., April 1, 1999; 162(7): 4157 - 4162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Guermonprez, D. Ladant, G. Karimova, A. Ullmann, and C. Leclerc Direct Delivery of the Bordetella pertussis Adenylate Cyclase Toxin to the MHC Class I Antigen Presentation Pathway J. Immunol., February 15, 1999; 162(4): 1910 - 1916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. H. Carbonetti, T. J. Irish, C. H. Chen, C. B. O'Connell, G. A. Hadley, U. McNamara, R. G. Tuskan, and G. K. Lewis Intracellular Delivery of a Cytolytic T-Lymphocyte Epitope Peptide by Pertussis Toxin to Major Histocompatibility Complex Class I without Involvement of the Cytosolic Class I Antigen Processing Pathway Infect. Immun., February 1, 1999; 67(2): 602 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Karimova, C. Fayolle, S. Gmira, A. Ullmann, C. Leclerc, and D. Ladant Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: Implication for the in vivo delivery of CD8+ T cell epitopes into antigen-presenting cells PNAS, October 13, 1998; 95(21): 12532 - 12537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Goletz, K. R. Klimpel, N. Arora, S. H. Leppla, J. M. Keith, and J. A. Berzofsky Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein PNAS, October 28, 1997; 94(22): 12059 - 12064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sedlik, M.-F. Saron, J. Sarraseca, I. Casal, and C. Leclerc Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells PNAS, July 8, 1997; 94(14): 7503 - 7508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Saron, C. Fayolle, P. Sebo, D. Ladant, A. Ullmann, and C. Leclerc Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus PNAS, April 1, 1997; 94(7): 3314 - 3319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Basar, V. Havlicek, S. Bezouskova, M. Hackett, and P. Sebo Acylation of Lysine 983 Is Sufficient for Toxin Activity of Bordetella pertussis Adenylate Cyclase. SUBSTITUTIONS OF ALANINE 140 MODULATE ACYLATION SITE SELECTIVITY OF THE TOXIN ACYLTRANSFERASE CyaC J. Biol. Chem., January 5, 2001; 276(1): 348 - 354. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
